Nabriva Therapeutics plc (NBRVF)
OTCMKTS
· Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
At close: May 5, 2025
Nabriva Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|
Period Ending | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2013 - 2017 |
| Operating Revenue | 36.94 | 28.9 | 5.03 | 9.48 | 9.66 | Upgrade
|
| Revenue | 36.94 | 28.9 | 5.03 | 9.48 | 9.66 | Upgrade
|
| Revenue Growth (YoY) | 27.82% | 474.80% | -46.98% | -1.81% | 81.54% | Upgrade
|
| Cost of Revenue | 47.16 | 25.78 | 15.87 | 26.49 | 50.24 | Upgrade
|
| Gross Profit | -10.23 | 3.12 | -10.84 | -17 | -40.58 | Upgrade
|
| Selling, General & Admin | 45.26 | 51.65 | 55.29 | 62.49 | 41.74 | Upgrade
|
| Operating Expenses | 45.26 | 51.65 | 55.29 | 62.49 | 41.74 | Upgrade
|
| Operating Income | -55.49 | -48.53 | -66.13 | -79.49 | -82.33 | Upgrade
|
| Interest Expense | -0.7 | -0.9 | -1.65 | -3.39 | -0.13 | Upgrade
|
| Interest & Investment Income | - | - | - | - | 0.05 | Upgrade
|
| Currency Exchange Gain (Loss) | 0.57 | 0.47 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | 1.19 | 0.22 | -0.27 | Upgrade
|
| EBT Excluding Unusual Items | -55.62 | -48.96 | -66.59 | -82.66 | -82.68 | Upgrade
|
| Other Unusual Items | - | - | -2.76 | - | - | Upgrade
|
| Pretax Income | -55.62 | -48.96 | -69.35 | -82.66 | -114.73 | Upgrade
|
| Income Tax Expense | 1.57 | 0.49 | 0.14 | 0.1 | 0.05 | Upgrade
|
| Net Income | -57.19 | -49.45 | -69.48 | -82.76 | -114.78 | Upgrade
|
| Net Income to Common | -57.19 | -49.45 | -69.48 | -82.76 | -114.78 | Upgrade
|
| Shares Outstanding (Basic) | 3 | 2 | 1 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 3 | 2 | 1 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 54.67% | 237.48% | 73.12% | 46.07% | 70.28% | Upgrade
|
| EPS (Basic) | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | Upgrade
|
| EPS (Diluted) | -21.32 | -28.52 | -135.23 | -278.86 | -564.91 | Upgrade
|
| Free Cash Flow | -36.92 | -59.58 | -71.44 | -71.95 | -72.95 | Upgrade
|
| Free Cash Flow Per Share | -13.77 | -34.36 | -139.05 | -242.43 | -359.05 | Upgrade
|
| Gross Margin | -27.69% | 10.79% | -215.66% | -179.35% | - | Upgrade
|
| Operating Margin | -150.24% | -167.95% | -1315.42% | -838.40% | -852.60% | Upgrade
|
| Profit Margin | -154.83% | -171.14% | -1382.22% | -872.95% | -1188.69% | Upgrade
|
| Free Cash Flow Margin | -99.97% | -206.20% | -1421.20% | -758.92% | -755.51% | Upgrade
|
| EBITDA | -55.27 | -48.17 | -65.71 | -79.09 | -81.82 | Upgrade
|
| EBITDA Margin | -149.65% | -166.71% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.22 | 0.36 | 0.42 | 0.4 | 0.51 | Upgrade
|
| EBIT | -55.49 | -48.53 | -66.13 | -79.49 | -82.33 | Upgrade
|
| EBIT Margin | -150.24% | -167.95% | - | - | - | Upgrade
|
| Revenue as Reported | 36.94 | 28.9 | 5.03 | 9.48 | 9.66 | Upgrade
|
Updated Oct 19, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.